The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia

被引：7

作者：

Horvitz-Lennon, Marcela ^{[1
]}

Predmore, Zachary ^{[1
,3
]}

Orr, Patrick ^{[1
,5
]}

Hanson, Mark ^{[2
,4
]}

Hillestad, Richard ^{[2
]}

Durkin, Mike ^{[6
]}

El Khoury, Antoine C. ^{[6
]}

Mattke, Soeren ^{[1
,4
]}

机构：

[1] RAND Corp, 20 Pk Plaza,Suite 920, Boston, MA 02116 USA

[2] RAND Corp, Santa Monica, CA USA

[3] Johns Hopkins Univ, Baltimore, MD USA

[4] Univ Southern Calif, Los Angeles, CA 90007 USA

[5] Informat Mapping, Boston, MA USA

[6] Janssen Sci Affairs LLC, Titusville, NJ USA

来源：

ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH | 2020年 / 47卷 / 03期

关键词：

Schizophrenia; Treatment adherence; Early detection; Simulation; QUALITY-OF-LIFE; UNTREATED PSYCHOSIS; 1ST-EPISODE SCHIZOPHRENIA; EARLY INTERVENTION; NEGATIVE SYMPTOMS; MENTAL-ILLNESS; UNITED-STATES; DURATION; DISORDERS; PEOPLE;

D O I：

10.1007/s10488-019-00990-7

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

The impact of initiatives aimed at reducing time in untreated psychosis during early-stage schizophrenia will be unknown for many years. Thus, we simulate the effect of earlier treatment entry and better antipsychotic drug adherence on schizophrenia-related hospitalizations, receipt of disability benefits, competitive employment, and independent/family living over a ten-year horizon. We predict that earlier treatment entry reduces hospitalizations by 12.6-14.4% and benefit receipt by 7.0-8.5%, while increasing independent/family living by 41.5-46% and employment by 42-58%. We predict larger gains if a pro-adherence intervention is also used. Our findings suggest substantial benefits of timely and consistent early schizophrenia care.

引用

页码：357 / 365

页数：9

共 50 条

[31] Long-term treatment goals in schizophrenia
Gaebel, W.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S665 - S665
[32] Olanzapine in the long-term treatment of schizophrenia
Kane, J
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 : 26 - 29
[33] LONG-TERM TREATMENT OF SCHIZOPHRENIA WITH PENFLURIDOL
HARING, C
MEDIZINISCHE WELT, 1977, 28 (13): : 639 - 642
[34] Sertindole in the long-term treatment of schizophrenia
Hale, Anthony S.
Azorin, Jean M.
Lemming, Ole M.
Maehlum, Eli
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2012, 27 (04) : 231 - 237
[35] Long-term treatment of chronic schizophrenia
不详
NERVENARZT, 2007, 78 (06): : 734 - 734
[36] THE LONG-TERM TREATMENT OF SCHIZOPHRENIA IN THE COMMUNITY
ROLLIN, HR
PRACTITIONER, 1982, 226 (1369) : 1330 - 1333
[37] NIACIN IN LONG-TERM TREATMENT OF SCHIZOPHRENIA
WITTENBORN, JR
WEBER, ESP
BROWN, M
ARCHIVES OF GENERAL PSYCHIATRY, 1973, 28 (03) : 308 - 315
[38] COMPLIANCE IN THE LONG-TERM TREATMENT OF SCHIZOPHRENIA
KANE, JM
BORENSTEIN, M
PSYCHOPHARMACOLOGY BULLETIN, 1985, 21 (01) : 23 - 27
[39] Sertindole in the long-term treatment of schizophrenia
Maehlum, Eli
Hale, A.
Murray, R.
Azorin, J. -M.
NERVENARZT, 2007, 78 : 85 - 85
[40] Under-utilized opportunities to optimize medication management in long-term treatment of schizophrenia
Isohanni, Matti
Miettunen, Jouko
Jaaskelainen, Erika
Moilanen, Jani
Hulkko, Anja
Huhtaniska, Sanna
WORLD PSYCHIATRY, 2018, 17 (02): : 172 - 173

← 1 2 3 4 5 →